Incidence and Outcomes of COVID-19 in People With CKD : A Systematic Review and Meta-analysis
Copyright © 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved..
RATIONALE & OBJECTIVE: Coronavirus disease 2019 (COVID-19) disproportionately affects people with chronic diseases such as chronic kidney disease (CKD). We assessed the incidence and outcomes of COVID-19 in people with CKD.
STUDY DESIGN: Systematic review and meta-analysis by searching MEDLINE, EMBASE, and PubMed through February 2021.
SETTING & STUDY POPULATIONS: People with CKD with or without COVID-19.
SELECTION CRITERIA FOR STUDIES: Cohort and case-control studies.
DATA EXTRACTION: Incidences of COVID-19, death, respiratory failure, dyspnea, recovery, intensive care admission, hospital admission, need for supplemental oxygen, hospital discharge, sepsis, short-term dialysis, acute kidney injury, and fatigue.
ANALYTICAL APPROACH: Random-effects meta-analysis and evidence certainty adjudicated using an adapted version of GRADE (Grading of Recommendations Assessment, Development and Evaluation).
RESULTS: 348 studies (382,407 participants with COVID-19 and CKD; 1,139,979 total participants with CKD) were included. Based on low-certainty evidence, the incidence of COVID-19 was higher in people with CKD treated with dialysis (105 per 10,000 person-weeks; 95% CI, 91-120; 95% prediction interval [PrI], 25-235; 59 studies; 468,233 participants) than in those with CKD not requiring kidney replacement therapy (16 per 10,000 person-weeks; 95% CI, 4-33; 95% PrI, 0-92; 5 studies; 70,683 participants) or in kidney or pancreas/kidney transplant recipients (23 per 10,000 person-weeks; 95% CI, 18-30; 95% PrI, 2-67; 29 studies; 120,281 participants). Based on low-certainty evidence, the incidence of death in people with CKD and COVID-19 was 32 per 1,000 person-weeks (95% CI, 30-35; 95% PrI, 4-81; 229 studies; 70,922 participants), which may be higher than in people with CKD without COVID-19 (incidence rate ratio, 10.26; 95% CI, 6.78-15.53; 95% PrI, 2.62-40.15; 4 studies; 18,347 participants).
LIMITATIONS: Analyses were generally based on low-certainty evidence. Few studies reported outcomes in people with CKD without COVID-19 to calculate the excess risk attributable to COVID-19, and potential confounders were not adjusted for in most studies.
CONCLUSIONS: The incidence of COVID-19 may be higher in people receiving maintenance dialysis than in those with CKD not requiring kidney replacement therapy or those who are kidney or pancreas/kidney transplant recipients. People with CKD and COVID-19 may have a higher incidence of death than people with CKD without COVID-19.
| Errataetall: |
CommentIn: Am J Kidney Dis. 2021 Dec;78(6):777-779. - PMID 34627640 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
American journal of kidney diseases : the official journal of the National Kidney Foundation - 78(2021), 6 vom: 17. Dez., Seite 804-815 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chung, Edmund Y M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.12.2021 Date Revised 28.09.2022 published: Print-Electronic CommentIn: Am J Kidney Dis. 2021 Dec;78(6):777-779. - PMID 34627640 Citation Status MEDLINE |
|---|
| doi: |
10.1053/j.ajkd.2021.07.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329091573 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329091573 | ||
| 003 | DE-627 | ||
| 005 | 20231225204342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1053/j.ajkd.2021.07.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1096.xml |
| 035 | |a (DE-627)NLM329091573 | ||
| 035 | |a (NLM)34364906 | ||
| 035 | |a (PII)S0272-6386(21)00771-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chung, Edmund Y M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence and Outcomes of COVID-19 in People With CKD |b A Systematic Review and Meta-analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.12.2021 | ||
| 500 | |a Date Revised 28.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Am J Kidney Dis. 2021 Dec;78(6):777-779. - PMID 34627640 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a RATIONALE & OBJECTIVE: Coronavirus disease 2019 (COVID-19) disproportionately affects people with chronic diseases such as chronic kidney disease (CKD). We assessed the incidence and outcomes of COVID-19 in people with CKD | ||
| 520 | |a STUDY DESIGN: Systematic review and meta-analysis by searching MEDLINE, EMBASE, and PubMed through February 2021 | ||
| 520 | |a SETTING & STUDY POPULATIONS: People with CKD with or without COVID-19 | ||
| 520 | |a SELECTION CRITERIA FOR STUDIES: Cohort and case-control studies | ||
| 520 | |a DATA EXTRACTION: Incidences of COVID-19, death, respiratory failure, dyspnea, recovery, intensive care admission, hospital admission, need for supplemental oxygen, hospital discharge, sepsis, short-term dialysis, acute kidney injury, and fatigue | ||
| 520 | |a ANALYTICAL APPROACH: Random-effects meta-analysis and evidence certainty adjudicated using an adapted version of GRADE (Grading of Recommendations Assessment, Development and Evaluation) | ||
| 520 | |a RESULTS: 348 studies (382,407 participants with COVID-19 and CKD; 1,139,979 total participants with CKD) were included. Based on low-certainty evidence, the incidence of COVID-19 was higher in people with CKD treated with dialysis (105 per 10,000 person-weeks; 95% CI, 91-120; 95% prediction interval [PrI], 25-235; 59 studies; 468,233 participants) than in those with CKD not requiring kidney replacement therapy (16 per 10,000 person-weeks; 95% CI, 4-33; 95% PrI, 0-92; 5 studies; 70,683 participants) or in kidney or pancreas/kidney transplant recipients (23 per 10,000 person-weeks; 95% CI, 18-30; 95% PrI, 2-67; 29 studies; 120,281 participants). Based on low-certainty evidence, the incidence of death in people with CKD and COVID-19 was 32 per 1,000 person-weeks (95% CI, 30-35; 95% PrI, 4-81; 229 studies; 70,922 participants), which may be higher than in people with CKD without COVID-19 (incidence rate ratio, 10.26; 95% CI, 6.78-15.53; 95% PrI, 2.62-40.15; 4 studies; 18,347 participants) | ||
| 520 | |a LIMITATIONS: Analyses were generally based on low-certainty evidence. Few studies reported outcomes in people with CKD without COVID-19 to calculate the excess risk attributable to COVID-19, and potential confounders were not adjusted for in most studies | ||
| 520 | |a CONCLUSIONS: The incidence of COVID-19 may be higher in people receiving maintenance dialysis than in those with CKD not requiring kidney replacement therapy or those who are kidney or pancreas/kidney transplant recipients. People with CKD and COVID-19 may have a higher incidence of death than people with CKD without COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Coronavirus disease 2019 (COVID-19) | |
| 650 | 4 | |a chronic kidney disease (CKD) | |
| 650 | 4 | |a cohort studies | |
| 650 | 4 | |a dialysis patients | |
| 650 | 4 | |a end-stage kidney disease (ESKD) | |
| 650 | 4 | |a incidence | |
| 650 | 4 | |a meta-analysis | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a respiratory failure | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | |
| 650 | 4 | |a systematic review | |
| 700 | 1 | |a Palmer, Suetonia C |e verfasserin |4 aut | |
| 700 | 1 | |a Natale, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Krishnan, Anoushka |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, Tess E |e verfasserin |4 aut | |
| 700 | 1 | |a Saglimbene, Valeria M |e verfasserin |4 aut | |
| 700 | 1 | |a Ruospo, Marinella |e verfasserin |4 aut | |
| 700 | 1 | |a Au, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Jayanti, Sumedh |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Jie Deng, Danny Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Chui, Juanita |e verfasserin |4 aut | |
| 700 | 1 | |a Higgins, Gail Y |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Allison |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Germaine |e verfasserin |4 aut | |
| 700 | 1 | |a Teixeira-Pinto, Armando |e verfasserin |4 aut | |
| 700 | 1 | |a Hodson, Elisabeth M |e verfasserin |4 aut | |
| 700 | 1 | |a Craig, Jonathan C |e verfasserin |4 aut | |
| 700 | 1 | |a Strippoli, Giovanni F M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of kidney diseases : the official journal of the National Kidney Foundation |d 1982 |g 78(2021), 6 vom: 17. Dez., Seite 804-815 |w (DE-627)NLM012600814 |x 1523-6838 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2021 |g number:6 |g day:17 |g month:12 |g pages:804-815 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1053/j.ajkd.2021.07.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2021 |e 6 |b 17 |c 12 |h 804-815 | ||